Abbott Laboratories (ABT) lifted its full-year earnings outlook on Thursday as the healthcare firm reported second-quarter results above market estimates.
Adjusted earnings are now anticipated between $5.45 and $5.60 per share for 2026, the company said, up from its previous guidance of $5.38 to $5.58. The consensus on FactSet is for non-GAAP EPS of $5.47.
Abbott continues to expect comparable sales growth of 6.5% to 7.5% for the current year. Comparable sales include the impact of Exact Sciences, a cancer diagnostics firm that Abbott acquired in March.
The company's shares climbed 12% in Thursday trade, although the stock has lost 21% so far this year.
For the three-month period ended June, Abbott's adjusted EPS rose to $1.31 from $1.26 the year before, surpassing the Street's view for $1.28. Sales climbed 13% to $12.59 billion, topping the average analyst estimate of $12.52 billion. Comparable sales rose 4.8%.
"Our second-quarter results reflect the momentum we are building," Chief Executive Robert Ford said in an earnings release. "We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year."
Diagnostics sales jumped 42% year over year to $3.09 billion, while the nutrition segment declined 3.1% to $2.14 billion amid lower volume and the impact of pricing actions taken in the fourth quarter of 2025, Abbott said. Revenue in the established pharmaceuticals division added 8.4% to almost $1.5 billion.
Sales in the medical devices business grew 9% to $5.85 billion, buoyed by double-digit gains in rhythm management, electrophysiology and diabetes care, according to Abbott.
For the third quarter, the company forecasts adjusted EPS of $1.38 to $1.46, while the Street is looking for $1.42.
Price: $100.43, Change: $+11.16, Percent Change: +12.50%



